Srinivasa Movva, MD
Internal Medicine · Atlantic Highlands, NJNPI 1699720508
Payments from drug & device makers
Across 650 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$2K
- AbbVie$1K
- GSK$1K
- Amgen$734
- Pfizer$576
- plus $4K from 28 others
What the payments were for
- Food & beverage$11,723100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 102 | $2,518 |
| Novo Nordisk | 120 | $1,845 |
| AbbVie(2 entities) | 78 | $1,285 |
| GSK | 63 | $1,145 |
| Amgen | 28 | $734 |
| Pfizer | 37 | $576 |
| Lilly USA, LLC | 32 | $468 |
| Kowa Pharmaceuticals America, Inc. | 35 | $421 |
| Boehringer Ingelheim | 22 | $392 |
| Amarin Pharma, Inc. | 20 | $364 |
| Bayer | 13 | $298 |
| Merck | 19 | $255 |
| Johnson & Johnson(2 entities) | 11 | $186 |
| E.r. Squibb & Sons, L.L.C. | 7 | $184 |
| Novartis | 10 | $149 |
| Exact Sciences | 6 | $140 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $84 |
| Paratek Pharmaceuticals, Inc. | 5 | $65 |
| Astellas Pharma US Inc | 3 | $62 |
| Davol Inc. | 1 | $60 |
| Idorsia Pharmaceuticals US Inc | 4 | $59 |
| Abbott | 3 | $48 |
| Phathom Pharmaceuticals, Inc. | 3 | $43 |
| IBSA Pharma Inc. | 3 | $40 |
| Cumberland Pharmaceuticals, Inc. | 2 | $39 |
| Sanofi Pasteur Inc. | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Baxter Healthcare | 1 | $20 |
| Renalytix AI, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $19 |
| Modernatx, Inc. | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,723 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 109 | $118,586 |
| EliquisApixaban | 78 | $76,080 |
| OzempicSemaglutide | 44 | $55,071 |
| JardianceEmpagliflozin | 50 | $41,525 |
| JanuviaSitagliptin Phosphate | 29 | $39,474 |
| XareltoRivaroxaban | 25 | $28,023 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $21,842 |
| MounjaroTirzepatide | 19 | $20,226 |
| RybelsusSemaglutide | 13 | $15,807 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $13,968 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $12,333 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,643 |
| VascepaIcosapent Ethyl | 11 | $7,017 |
| TradjentaLinagliptin | 12 | $6,112 |
| Pantoprazole Sodium | 360 | $5,868 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $2,518 | $140,428144 claims |
| PfizerEliquis | $576 | $76,08078 claims |
| Novo NordiskOzempic, Rybelsus | $1,845 | $70,87857 claims |
| Boehringer IngelheimJardiance, Tradjenta | $392 | $47,63762 claims |
| MerckJanuvia | $255 | $39,47429 claims |
| Johnson & JohnsonXarelto | $186 | $28,02325 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,145 | $24,44046 claims |
| Lilly USA, LLCMounjaro | $468 | $20,22619 claims |
| Astellas Pharma US IncMyrbetriq | $62 | $5,64112 claims |
| AbbVieSynthroid | $1,285 | $3,22353 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Atlantic Highlands
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.